University of South Florida

Scholar Commons
Mental Health Law & Policy Faculty Publications

Mental Health Law & Policy

2018

The Moderating Relationship of Comorbid
Psychopathology and Treatment Outcome for
Young Adult Offenders in Drug Court
Patrick McGonigal
University of South Florida, ptmcgonigal@gmail.com

Kathleen A. Moore
University of South Florida, kamoore@usf.edu

Matthew Scott Young
University of South Florida, syoung1@usf.edu

Follow this and additional works at: http://scholarcommons.usf.edu/mhlp_facpub
Part of the Health Law and Policy Commons, and the Mental Disorders Commons
Scholar Commons Citation
McGonigal, Patrick; Moore, Kathleen A.; and Young, Matthew Scott, "The Moderating Relationship of Comorbid Psychopathology
and Treatment Outcome for Young Adult Offenders in Drug Court" (2018). Mental Health Law & Policy Faculty Publications. 826.
http://scholarcommons.usf.edu/mhlp_facpub/826

This Article is brought to you for free and open access by the Mental Health Law & Policy at Scholar Commons. It has been accepted for inclusion in
Mental Health Law & Policy Faculty Publications by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.

Research Article

iMedPub Journals

Dual Diagnosis: Open Access

http://www.imedpub.com/

ISSN 2472-5048

2018
Vol.3 No.2:7

DOI: 10.4172/2472-5048.100041

The Moderating Relationship of Comorbid Psychopathology and
Treatment Outcome for Young Adult Offenders in Drug Court
Patrick T. McGonigal*, Kathleen A. Moore, Matthew Scott Young
Florida Mental Health Institute Tampa, University of South Florida, FL 33620
*Corresponding author: Patrick T. McGonigal, Florida Mental Health Institute Tampa, University of South Florida, USA, Tel: (401) 444-3402; Fax:
(401) 444-8836; E-mail: ptmcgonigal@gmail.com
Received date: May 15, 2018; Accepted date: May 31, 2018; Published date: June 7, 2018
Citation: McGonigal PT, Moore KA, Young MS (2018) The moderating relationship of comorbid psychopathology and treatment outcome for young
adult offenders in drug court Dual Diagn Open AccVol.3 No.2:7.
Copyright: ©2018 McGonigal PT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract
Title: The moderating relationship of comorbid
psychopathology and treatment outcome for young adult
offenders in drug court.
Background: The drug court system is an alternative to
incarceration that provides offenders with non-violent,
substance motivated crimes with an opportunity to dismiss
their charges and undergo a rigorous substance abuse
treatment program. It is unknown whether drug court is
effective for young adult clients and the role of co-occurring
psychopathology within this context.
Methods: This study evaluated the overall effectiveness of a
drug court system applied to young adult offenders ages
18-26, and additionally explored the moderating
relationship of psychiatric symptoms on treatment
outcome. Seventy-four clients were assessed at baseline
and at 6-month follow-up.
Findings: Participants reported reductions in substance use
(M=35.51, SD=29.92; M=7.79, SD=17.83; t(71)=7.00,
p<0.001) and mental health symptoms (M=48.26, SD=36.49;
M=36.40, SD=37.99; t(71)=2.05, p<0.05) at follow-up.
Additionally, moderators of outcome were found based on
internalizing and externalizing mental health symptoms.
Conclusions: Drug court may be an effective alternative to
incarceration for young adults and may benefit higher
severity clients in particular.
Keywords: Substance abuse, Internalizing disorder, mental
health

Introduction
Since its inception, the American criminal justice system has
focused on punishing offenders to deter and prevent criminal
activity. In 2013, about 2 million American citizens were
incarcerated-approximately 716 people per 100,000 [1,2].
Contrary to expectations, incarceration has been consistently

demonstrated as widely ineffective for preventing recidivism
[3-5]. In particular, offenders with substance abuse issues have
become a growing concern within the criminal justice system.
Mandatory minimums on drug offenses, combined with the
rigorous conviction of non-violent drug offenders, have fueled
an extraordinary amount of incarcerated offenders with
addictions [6]; Offenders struggling with addictions are about
82% more likely to recidivate than non-addicted offenders upon
release [3]. Without adequate substance abuse and mental
health services, offenders with addictions are at a higher risk of
recidivism upon release into the community.
Adult drug court is a problem-solving court created to divert
offenders with substance abuse issues from incarceration by
focusing predominately on rehabilitation. The drug court system
is a collaborative effort between court personnel (e.g. judges,
drug court specialists, state attorneys, and public defenders),
treatment providers, independent evaluators, and offenders to
eliminate addictions. Eligible drug offenders are given the option
to participate in drug court; upon agreement, clients are
mandated to complete a rigorous and intensive treatment
regimen combined with ongoing random drug testing and
scheduled court appearances. Contingent upon their completion
of treatment, the drug court will dismiss their charges and
oftentimes expunge their criminal record. If an offender fails to
complete treatment, commits an additional crime or
consistently fails drug tests, the individual is convicted and
sentenced thereafter.
While most research literature suggests the effectiveness of
drug court [7-10], there is a scarce understanding on whether
these findings translate to young adult offenders whose
experiences are notably different given their developmental
context [11]. Additionally, existing research has yet to identify
specific characteristics of individuals that are more or less likely
to benefit from drug court. Identifying potential moderators of
treatment for this population has large implications for judicial
personnel, clinicians, and policy makers. In particular, cooccurring psychopathology is widely prevalent among
individuals with substance use disorders (up to 65%) [12]. Clients
with co-occurring psychopathology may respond more positively
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to comprehensive treatment models that factor underlying
disorders.

Gender
Male

35

36.6

Current study

Female

63

64.3

Age (years)

98

22.5 (2.21)

Caucasian

82

83.7

African-American

1

2.9

Hispanic/Latino

1

1

Mixed

12

12.2

Other

1

1

Less than high school diploma

57

58.2

High school diploma/GED

41

41.8

Associate’s degree

3

2.5

Bachelor’s degree

1

1

Vocational/trade certificate

14

14.3

Heterosexual

88

85.4

Homosexual, gay or lesbian

4

3.8

Bisexual

4

3.8

Non-sexual or asexual

2

1.9

Married

1

1

Living with someone as married

1

1

Married but living apart

5

4.8

Divorced

1

1

Legally separated

2

1.9

Single

88

85.4

Pregnant

4

3.9

The present study aims to resolve several disparities in
existing literature by evaluating the effectiveness of a young
adult drug court program in Florida and identifying potential
moderators of treatment outcome based on co-occurring
psychopathology. The intervention was a combined mental
health and substance abuse treatment program housed within
an adult drug court that targets non-violent young adult
offenders (ages 18-26) with crimes associated with illegal
substances.
This study had several objectives and components including
to: 1) evaluate the initial six-month effectiveness of a young
adult drug court model by measuring clients’ overall substance
use and mental health symptomatology, and 2) determine if
baseline
psychopathology
moderated
the
program’s
effectiveness on outcome. All protocol and procedures were
approved by an IRB at the University of South Florida, and
informed consent was obtained from each participant before
any study activities were initiated.

Participants
Inclusion criteria for participating in the program include male
and female young adult offenders with drug motivated nonviolent felony charges. Sex offenders and violent/noncompliant
offenders are excluded from participating in the court. The
present study investigated client progress over a six-month
period of time since beginning substance abuse treatment.
Clients were mandated to undergo intensive treatment in three
stages: (1) three months at three times a week, then (2) three
months at two times a week, and finally (3) three to six months
of aftercare with individual therapy, support groups, and drug
tests. Of the participants enrolled in the program, 98 completed
baseline assessments, and 74 completed both baseline and sixmonth follow-up measures at the time of analysis. As can be
seen in Table 1, about 64% were female, the average age was
about 22.5 years old, and approximately 84% were Caucasians.
More than half (58%) did not complete high school, with 42%
completing high school or GED. 85% of the sample were single.
Those that completed both baseline and follow-up measures
did not differ in most demographic variables (all ps>0.05),
however those that completed treatment were more likely to
have completed high school (p<0.05). Those who completed
follow-up assessments endorsed more symptoms of
psychopathology at baseline than those who did not (p<0.01). In
contrast, participants who did not complete follow-up measures
had higher reported cocaine use (p<0.001).
Table 1: Demographics characteristics (n = 98).

2

Education (years)

Sexual Orientation

Method

Characteristic

Race/Ethnicity

n

% or Mean (SD)

Marital status

Note: Percentages represent valid % due to limited missing data.

Measures
This study conducted an evaluation using data obtained from
the measures described below. Data were collected from each
participant at baseline upon entering drug court treatment and
subsequently six months later.
The Global Appraisal of Individual Needs-Q3: MI assessment
(GAIN-Q3) The GAIN assessment is a brief comprehensive
evaluation tool administered via a 20-40-minute structured
clinical interview by a trained clinical research assistant [13]. The
interview is divided into several components assessing school
problems, work problems, physical health, sources of stress, risk
behaviours for infectious diseases, mental health, substance use,
and crime and violence. These analyses focused on substance
This article is available from: https://dual-diagnosis.imedpub.com/
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use measured by the GAIN-Q3. Cronbach’s alpha internal
consistency reliability scores were fair, α=0.66 at baseline and
α=0.65 at follow-up.
Brief Symptom Inventory (BSI): The BSI is a 53 item selfreport measure that assesses overall mental health functioning
[14]. The BSI is divided into nine subscales that measure
symptoms of (1) somatization, (2) obsessive compulsion, (3)
interpersonal sensitivity, (4) depression, (5) anxiety, (6) hostility,
(7) phobic anxiety, (8) paranoid ideation, and (9) psychoticism.
Internal consistency reliability scores were very strong,
Cronbach’s α=0.96 at baseline and follow-up.

2018
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Symptoms included in analyses were further characterized as
impairing and distressing; impairment and distress were
respectively defined as symptoms that prevent the client from
fulfilling daily responsibilities, and symptoms that create a
significant subjective disturbance. Second, a series of between
subjects repeated measures analyses of variance (ANOVAs) were
performed to determine if various outcomes were moderated as
reflected by significant group by time interactions; third, when
significant predictors were identified, additional paired samples
t-tests were used as follow-up tests to help further understand
the nature of the moderating relationships.

Results

Analyses
Descriptive statistics were used to characterize the sample. To
answer questions associated with treatment effectiveness
paired samples t-tests were conducted on several variables
associated with substance use and mental health
symptomatology using SPSS 22 software. To investigate
moderators of treatment outcome via presenting
psychopathology, participants were categorized into two groups:
lower severity (by reporting internalizing disorder symptoms for
less than 45 out of 90 days at baseline) and higher severity (by
reporting internalizing disorder symptoms for 45 days or more
out of 90 days at baseline). Internalizing disorder symptoms
included depressive symptoms (i.e., low mood, hopelessness),
insomnia, anxiety (i.e., nervousness, panic-symptoms), posttraumatic stress symptoms, suicidality, and auditory/visual
hallucinations.

Substance use
Clients reported the total number of days they used any
alcohol or drugs within the last 90 days at baseline and 6-month
follow-up. Clients reported reductions in overall substance use
(M=35.51, SD=29.92; M=7.79, SD=17.83; t(71)=7.00, p<0.001).
Similarly, clients reported decreases in alcohol use (M=14.67,
SD=21.93; M=1.96, SD=7.83; t(72)=4.64, p<0.001), heroin,
methadone, and opioid use (M=13.51, SD=21.67; M=3.30,
SD=11.68; t(72)=3.78, p<0.001), and a variable representing
other drug use (M=7.19, SD=17.41; M=1.27, SD=7.11;
t(72)=2.85, p<0.01) (Table 2).

Table 2: Client substance use outcomes within the past 90 Days at baseline and 6 months after program enrollment (n=74).
Participants
6 months
enrollment

Baseline

after

program
Significance

n

M (SD)

n

M (SD)

Overall Substance Use***

72

35.51 (29.92)

72

7.79 (17.83)

t=7.00 (df=71) p<.001

Alcohol***

73

14.67 (21.93)

73

1.96 (7.83)

t= 4.64 (df=72) p<.001

Heroin, Methadone, or Opioid***

73

13.51 (21.67)

72

3.30 (11.68)

t=3.78 (df=72) p<.001

Other drug use**

73

7.19 (17.41)

73

1.27 (7.11)

t=2.85 (df=72) p<.01

Cocaine/Crack

72

3.65 (11.56)

72

1.28 (8.42)

t=1.45 (df=71) p=.153

*p<.05; **p<.01; ***p<.001

Mental health symptomatology
In addition to reductions in substance use, clients reported
overall reductions in internalizing disorder symptoms (M=48.26,
SD=36.49; M=36.40, SD=37.99; t(71)=2.05, p<0.05) within 90
days of their assessment. Participants also reported decreases in
symptoms on the BSI assessment’s global severity index
(M=0.59, SD=0.71; M=0.44, SD=0.56; t(73)=2.45, p<0.01).

Additional BSI subscale reductions were found in somatization
(M=0.52, SD=0.75; M=0.29, SD=0.44; t(73)=3.55, p<0001),
anxiety (M=0.62, SD=0.84; M=0.42, SD=0.65; t(73)=2.47,
p<0.01), psychoticism (M=0.52, SD=0.73; M=0.36, SD=0.58;
t(73)=2.25, p<0.05), as well as phobic anxiety (M=0.35, SD=0.69;
M=0.22, SD=0.49; t(73)=1.98, p=0.05) (Table 3).

Table 3: Client mental health outcomes at baseline and 6 months after program enrollment (n=74).

© Under License of Creative Commons Attribution 3.0 License
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Participants
Baseline

6
months
enrollment

after

program

Significance

n

M (SD)

n

M (SD)

72

48.26 (36.50)

72

36.40 (37.99)

t=2.05 (df=71) p=0.04

74

0.52 (0.75)

74

29 (0.44)

t= 3.55 (df=73) p=0.001

Anxiety**

74

0.62 (0.84)

74

0.42 (0.65)

t=2.47 (df=73) p=0.01

Phobic Anxiety*

74

0.35 (0.69)

74

0.22 (0.49)

t=1.98 (df=73) p=0.05

Psychoticism*

74

0.52 (0.73)

74

0.36 (0.58)

t=2.25 (df=73) p=0.02

Global Severity Index**

74

0.59 (0.71)

74

0.44 (0.56)

t=2.45 (df=73) p=0.01

Internalizing Disorder Symptoms1*
Brief Symptom Inventory

Somatization***

Symptoms were assessed within the last 90 days of assessment. *p<0.05; **p<0.01; ***p<0.001

Table 4: Client predictors of mental health outcomes at baseline and 6 months after program enrollment (n=74).

4

Low Internalizing Disorder
Symptoms

High
Internalizing
Disorder Symptoms

Between
Subjects
Measures ANOVAs

Baseline

6 Months

Baseline

6 Months

time

M (SD)

M (SD)

M (SD)

M (SD)

F-value
value)

Brief
Symptom
Inventory
Global
Severity Index

0.2 (0.28)

0.35 (0.44)

0.91
(0.79)

0.5 (0.63)

Somatization

0.18 (0.35)

0.22 (0.36)

0.78
(0.87)

ObsessiveCompulsive

0.21 (0.38)

0.47 (0.6)

Interpersonal
Sensitivity

0.15 (0.3)

Depression

Repeated
Follow-up paired samples t-tests

Time x group

Low Internal

High Internal

F-value (p-value)

t-value
value)

t-value
value)

5.15 (0.026)

24.96 (0.000)

-2.68 (0.012)

4.56 (0.000)

0.34
(0.49)

11.87 (0.001)

16.92 (0.000)

-1.00 (0.325)

4.42 (0.000)

1.28
(1.05)

0.76
(0.99)

1.99 (0.163)

17.40 (0.000)

-3.18 (0.003)

3.38 (0.002)

0.32 (0.53)

0.9 (1.08)

0.49
(0.79)

1.96 (0.17)

11.64 (0.001)

-2.01 (0.053)

3.00 (0.005)

0.19 (0.33)

0.36 (0.56)

0.96
(0.97)

0.59
(0.89)

1.48 (0.228)

11.04 (0.001)

-1.83 (0.077)

2.96 (0.005)

Anxiety

0.24 (0.40)

0.35 (0.53)

0.92
(0.98)

0.48
(0.74)

5.10 (0.027)

14.25 (0.000)

-1.81 (0.08)

3.63 (0.001)

Hostility

0.21 (0.36)

0.50 (0.78)

0.68
(0.75)

0.37
(0.50)

0.030 (0.86)

16.13 (0.000)

-2.32 (0.027)

3.48 (0.001)

Phobic Anxiety

0.04 (0.13)

0.12 (0.36)

0.60
(0.85)

0.31
(0.55)

3.06 (0.085)

8.60 (0.005)

-1.48 (0.148)

2.8 (0.008)

Paranoid Ideation

0.22 (0.36)

0.41 (0.52)

0.94
(0.91)

0.54
(0.74)

1.69 (0.199)

14.62 (0.000)

-2.71 (0.011)

3.14 (0.003)

Psychoticism

0.15 (0.37)

0.27 (0.49)

0.82
(0.81)

0.44
(0.64)

4.07 (0.047)

14.39 (0.000)

-1.45 (0.157)

3.88 (0.000)

Overall
Use

32.48
(30.26)

7.33 (18.63)

38.08
(29.79)

8.18
(17.37)

47.54 (0.000)

0.35 (0.554)

Alcohol

14.55
(21.35)

2.42 (10.44)

14.77
(22.67)

1.58
(4.82)

20.85 (0.000)

0.04 (0.846)

Crack/Cocaine

5.30 (15.75)

0.48 (2.61)

2.26
(6.03)

1.95
(11.21)

2.45 (0.122)

1.90 (0.173)

Heroin, Methadone or
Opioid

17.03
(25.29)

3.15 (11.20)

10.60
(17.96)

3.43
(12.21)

15.24 (0.000)

1.55 (0.218)

Other Drug Use

4.03 (13.25)

1.94 (10.28)

9.8
(20.00)

0.72
(2.44)

7.37 (0.008)

2.88 (0.094)

Substance

(p-

(p-

(p-
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Analyses were then conducted on mental health
symptomatology to identify moderators of treatment outcome.
As seen in Table 4, between subjects repeated measures
ANOVAs suggested that clients with higher levels of internalizing
disorder complaints reported overall more success at reducing
psychopathology during substance abuse treatment determined
by the BSI. These results were significant on all nine subscales of
the measure. Follow-up paired samples t-tests demonstrated
that clients with low internalizing disorder symptoms reported
statistically significant increases in psychopathology after six
months across five BSI subscales. Similar analyses on substance
use did not yield significant results, suggesting that clients are
reducing substance use at comparable rates regardless of their
baseline level of internalizing disorder symptoms.

Discussion
This study found that after completing drug court, young
adult participants reported reductions in frequency of overall
substance use, and internalizing disorder symptoms at six-month
follow-up. These findings compliment previous literature on
drug court effectiveness [7-10].
More unique to this study is the focus on young adult
offenders ages 18-26. Whereas a disparity in drug court
literature includes an independent examination of the young
adult population, this study evaluated young adults exclusively
and found significant effects. Specifically, our clients expressed
reductions in overall substance use, alcohol, heroin, opioid,
methadone, and other drug use.
This study investigated the effect of drug court on mental
health symptomatology and found that clients reported
reductions on internalizing disorder symptoms from baseline to
six-month follow-up. This finding was also reflected at significant
levels within subscales of the Brief Symptom Inventoryspecifically somatization, anxiety, phobic anxiety, psychoticism,
and the global severity index. Additionally, our sample’s average
score at baseline on the Brief Symptom Inventory’s global
severity index is 0.59. Compared to adult non-patients, our
sample scored at or above 82% of this population, suggesting
that our sample presented greater symptoms of
psychopathology than a normative sample [14].
The results of this study also suggest potential moderators of
treatment outcome dependent upon baseline mental health
characteristics. The evidence above suggests that clients with
more impairing and distressing internalizing disorder symptoms
at baseline were more successful in reducing psychopathology
over the course of six months in treatment compared to clients
with less severe symptoms. Further, this study found those with
less severe symptoms at intake reported greater levels of
psychopathology over the course of treatment. These
moderation findings may have emerged for several reasons;
first, clinicians may recognize a greater need to assist individuals
with more severe symptoms at baseline and therefore direct
more of their resources to this group of clients. Second, drug
courts were designed to serve high risk offenders; according to
the criminological construct called the “risk principle,” intensive
court monitoring would be expected to achieve the greatest
© Under License of Creative Commons Attribution 3.0 License
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benefits for high-risk offenders with more severe mental health
and drug use histories, but may be unnecessary or even
contraindicated for low-risk offenders [15,16]. It is possible that
participants classified in the low distress group were lower risk
individuals who would have been better served in an alternate
diversion program with less requirements than a drug court.
Consistent with this possibility, Lowenkamp, Latessa, and
Hostlinger reviewed several studies investigating the risk
principle and found that intensive programs that included a
large percentage of low-risk offenders were more likely to have
poorer outcomes than those that were populated by a greater
proportion of high-risk offenders [17]. It should be noted that
while differences between these groups were found in
internalizing disorder symptoms, no differences were found in
other areas (i.e. substance use, criminal justice involvement).
The limitations of this study warrant mention and should be
utilized as a foundation for improving future research on drug
courts. Of importance, the results of this study are subject to a
certain degree of bias as all responses are based on self-report
measures. This is especially important to consider in a context
such as drug court where responses may be compromised by
external influences. Unfortunately, it was beyond the scope of
this study to include results from mandated drug tests, thus to
compound this study, future evaluations should include these
measures. The results from this study cannot assume causation
and can only infer associations due to a lack of control group.
Future studies may consider using a waiting-list control group, or
a comparison group representing incarcerated drug offenders to
compare the effects of drug court to incarceration. These
limitations notwithstanding, these findings complement other
results in this area of research, and further highlights in the
importance of comorbid psychopathology in drug court.
The implications of this study are relevant for drug court
professionals, and policy makers. The results of this evaluation
strengthen previous research on drug court effectiveness and
provide additional findings on young adult offenders and
comorbid psychopathology. This research suggests that
alternatives to incarceration can be effective for at-risk and
underserved populations-especially among substance abusers
with drug motivated criminal histories. Policy makers interested
in criminal justice reform may take an interest in the results of
this study, particularly in regard to the moderation findings
which may reflect the Risk-Needs-Responsivity (RNR) nature of
drug court systems.
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